Drug Profile
Olaparib - AstraZeneca
Alternative Names: AZD 221; AZD-2281; KU-0059436; KU-59436; Lynparza; MK 7339Latest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator KuDOS Pharmaceuticals; University of Pennsylvania
- Developer AstraZeneca; Cancer Research UK; Dana-Farber Cancer Institute; European Network of Gynaecological Oncological Trial Groups; German Breast Group; Hospices Civils de Lyon; M. D. Anderson Cancer Center; Mario Negri Institute for Pharmacological Research; Massachusetts General Hospital; Merck & Co; Merck Sharp & Dohme; Myriad Genetic Laboratories; Myriad Genetics; National Cancer Institute (USA); National Institute of Oncology; Netherlands Cancer Institute; NHS Greater Glasgow and Clyde; Nordic Society of Gynaecological - Clinical Trial Unit; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Spanish Oncology Genito-Urinary Group; University Health Network; University of Manchester; University of Oxford; University of Sydney; University of Texas M. D. Anderson Cancer Center
- Class Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Ketones; Phthalazines; Piperazines; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Fallopian tube cancer; HER2 negative breast cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer
- Phase III Breast cancer; Colorectal cancer; Endometrial cancer; Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer
- Phase II/III Triple negative breast cancer
- Phase II Bladder cancer; Cervical cancer; Gastric cancer; Glioblastoma; Head and neck cancer; HER2 positive breast cancer; Osteosarcoma; Renal cell carcinoma; Solid tumours; Urogenital cancer
Most Recent Events
- 30 Jan 2024 Mirati Therapeutics initiates a phase Ib trial for Advanced solid tumors (Combination therapy, Late-stage disease, unresectable/Inoperable, Second-line therapy or greater) in the US (NCT06130254)
- 25 Jan 2024 Efficacy and adverse events data from the phase II BRCAAway trial in Prostate cancer were released by AstraZeneca
- 19 Dec 2023 National Center for Tumor Diseases, Heidelberg collaboration with AstraZeneca and PharmaMar completes a (phase) trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Germany (IV) (EudraCT2017-001755-31) (NCT03127215)